Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAND1 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CAND1 siRNA is a small interfering RNA (siRNA) duplex designed to target and silence the expression of Cullin-associated NEDD8-dissociated protein 1 (CAND1). CAND1 is a HEAT-repeat scaffold protein that regulates the assembly and dynamics of cullin-RING ubiquitin ligases (CRLs) by controlling the exchange of substrate-recognition F-box subunits. In laboratory research, CAND1 siRNA is utilized as a tool to study the role of CAND1 in various cancers, including HER2-positive breast cancer, pediatric hepatoblastoma, and prostate cancer. Knockdown of CAND1 via siRNA has been shown to reduce cell viability, induce cell-cycle arrest and apoptosis, and suppress tumor growth in preclinical models. It is used strictly as a research reagent and is not currently in clinical development.
- Other names
- CAND1-targeting siRNA duplexCAND-1-targeting siRNA duplexCAND 1-targeting siRNA duplexsiCAND1siCAND-1siCAND 1
Beyond the preview
Go deeper on CAND1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAND1 siRNA.